Literature DB >> 16650808

Gene transfer approaches for gynecological diseases.

Mari Raki1, Daniel T Rein, Anna Kanerva, Akseli Hemminki.   

Abstract

Gene transfer presents a potentially useful approach for the treatment of diseases refractory to conventional therapies. Various preclinical and clinical strategies have been explored for treatment of gynecological diseases. Given the direst need for novel treatments, much of the work has been performed with gynecological cancers and ovarian cancer in particular. Although the safety of many approaches has been demonstrated in early phase clinical trials, efficacy has been mostly limited so far. Major challenges include improving gene transfer vectors for enhanced and selective delivery and achieving effective penetration and spread within advanced and complex tumor masses. This review will focus on current and developmental gene transfer applications for gynecological diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650808     DOI: 10.1016/j.ymthe.2006.02.019

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  7 in total

1.  Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Authors:  Evanthia Galanis; Pamela J Atherton; Matthew J Maurer; Keith L Knutson; Sean C Dowdy; William A Cliby; Paul Haluska; Harry J Long; Ann Oberg; Ileana Aderca; Matthew S Block; Jamie Bakkum-Gamez; Mark J Federspiel; Stephen J Russell; Kimberly R Kalli; Gary Keeney; Kah Whye Peng; Lynn C Hartmann
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

2.  Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.

Authors:  Daniel T Rein; Anne Volkmer; Gerd Bauerschmitz; Ines M Beyer; Wolfgang Janni; Markus C Fleisch; Anne Kathrin Welter; Dirk Bauerschlag; Thomas Schöndorf; Martina Breidenbach
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-01       Impact factor: 4.553

3.  Genetic control of wayward pluripotent stem cells and their progeny after transplantation.

Authors:  Maija Kiuru; Julie L Boyer; Timothy P O'Connor; Ronald G Crystal
Journal:  Cell Stem Cell       Date:  2009-04-03       Impact factor: 24.633

4.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Authors:  Evanthia Galanis; Lynn C Hartmann; William A Cliby; Harry J Long; Prema P Peethambaram; Brigitte A Barrette; Judith S Kaur; Paul J Haluska; Ileana Aderca; Paula J Zollman; Jeff A Sloan; Gary Keeney; Pamela J Atherton; Karl C Podratz; Sean C Dowdy; C Robert Stanhope; Timothy O Wilson; Mark J Federspiel; Kah-Whye Peng; Stephen J Russell
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

5.  Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.

Authors:  Marko T Ahonen; Iulia Diaconu; Sari Pesonen; Anna Kanerva; Marc Baumann; Suvi T Parviainen; Brad Spiller; Vincenzo Cerullo; Akseli Hemminki
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

6.  Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.

Authors:  Yu Bai; Maling Gou; Tao Yi; Li Yang; Lili Liu; Xiaojuan Lin; Dan Su; Yuquan Wei; Xia Zhao
Journal:  Int J Med Sci       Date:  2015-05-08       Impact factor: 3.738

Review 7.  Oncolytic immunotherapy: where are we clinically?

Authors:  Akseli Hemminki
Journal:  Scientifica (Cairo)       Date:  2014-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.